AI Journal

AI Journal

AI Journal is an authoritative open source platform focusing on artificial intelligence and emerging technologies. It gathers insights and case studies from global industry leaders helping businesses and individuals understand how AI is reshaping the modern business landscape.

AI Journal's Articles

AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm

AARD Investors Have Opportunity to Join Aardvark Therapeutics, Inc. Fraud Investigation With the Schall Law Firm

LOS ANGELES–(BUSINESS WIRE)–$AARD—The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors

How to Choose the Best Affordable AI-Enhanced 3D Printers for Kids in 2026

How to Choose the Best Affordable AI-Enhanced 3D Printers for Kids in 2026

3D printing is no longer restricted to just adults and scientists, but is now becoming a popular hobby for kids. Not only as a hobby, but it has also become a perfect

Apple Intelligence, Galaxy AI, Gemini: Why Your AI-Powered Phone Is Worth Repairing

Apple Intelligence, Galaxy AI, Gemini: Why Your AI-Powered Phone Is Worth Repairing

Smartphones are no longer just devices for calls and messages. With Apple’s Apple Intelligence platform built into the iPhone 17 lineup, Samsung’s Galaxy AI integrated

How Spyne’s 24/7 AI Call Answering Service Boosts Car Dealers’ Profits

How Spyne’s 24/7 AI Call Answering Service Boosts Car Dealers’ Profits

Over the past few years, AI answering services have moved from experimental technology to essential business infrastructure because modern consumers expect immediate

Building Scalable AI-Powered Customer Support with Cloud Telephony

Building Scalable AI-Powered Customer Support with Cloud Telephony

Integrating cloud telephony with AI-driven customer support systems enables businesses to deliver faster, smarter, and more personalized communication across voice

Fractional CFO Services in Real Life in the AI Era

Fractional CFO Services in Real Life in the AI Era

Fractional cfo services get sold as a role, but bought for results. That mismatch is why so many owners and operators feel disappointed a few weeks in. They expected

Flexzo Ai and Island Doctors Announce Multi-Year, Multi-Site Partnership to Deploy AI-Driven Workforce Automation Across Florida

Flexzo Ai and Island Doctors Announce Multi-Year, Multi-Site Partnership to Deploy AI-Driven Workforce Automation Across Florida

Florida, United States, February 28, 2026 — Flexzo Ai, the AI-powered healthcare workforce platform transforming staffing economics in the United States, announced

Scaling AI Data Pipelines: The Strategic Role of Proxies in Machine Learning

Scaling AI Data Pipelines: The Strategic Role of Proxies in Machine Learning

Artificial intelligence models are only as robust as the raw information they consume. In the field of data engineering, acquiring diverse, high-fidelity datasets

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)

This is the first positive Phase 3 trial for WELIREG in earlier-stage disease, the first positive results for a HIF-2α inhibitor and immunotherapy combination and

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)

This is the first positive Phase 3 trial of a HIF-2 alpha inhibitor in combination with a multi-targeted tyrosine kinase inhibitor, the first for patients with